VIAVI Insider Sale: 9,927 Shares Disposed Under 10b5-1 Plan
Rhea-AI Filing Summary
Kevin Christopher Siebert, SVP General Counsel & Secretary of VIAVI Solutions Inc. (VIAV), reported a sale of 9,927 shares of the issuer's common stock on 09/25/2025. The sale was made pursuant to a Rule 10b5-1 stock trading plan dated September 10, 2024, and was executed in multiple trades at prices ranging from $12.08 to $12.27, with a weighted average sale price of $12.17. Following the reported transaction, the reporting person beneficially owned 84,598 shares. The Form 4 was signed by attorney-in-fact Donna T. Rossi.
Positive
- Sale executed under a Rule 10b5-1 plan, indicating a pre-established, non-discretionary trading arrangement
- Complete price range disclosure ($12.08 to $12.27) with weighted average price reported ($12.17)
- Form 4 filed with attorney-in-fact signature, demonstrating procedural compliance
Negative
- Reporting person disposed of 9,927 shares, reducing beneficial ownership from prior levels to 84,598 shares
- Transaction reflects insider liquidity, which may be interpreted by some investors as a reduction in insider holdings
Insights
TL;DR: Insider sale under a pre-established plan; transaction is factual reporting, not a discretionary sale.
The Form 4 discloses a routine disposition of 9,927 shares by the company's SVP General Counsel executed under a Rule 10b5-1 plan. Because the sale was pre-planned and executed across multiple trades at prices between $12.08 and $12.27, the filing documents the mechanics and resulting beneficial ownership of 84,598 shares. This disclosure supplies transparency on insider liquidity but does not provide forward-looking operational or financial information about the company.
TL;DR: Disclosure aligns with governance best practices; sale executed under a documented 10b5-1 plan.
The submission shows compliance with Section 16 reporting requirements and cites a 10b5-1 trading plan dated September 10, 2024, which indicates the disposition was prearranged. The filing includes the requisite price range disclosure and attestation via attorney-in-fact signature. From a governance perspective, the document meets standard disclosure norms but contains no indication of unusual timing or material noncompliance.